Abstract 1554P
Background
We conducted a clinical trial evaluating safety and efficacy of T-mab plus N-mab with S-1/Capecitabine plus oxaliplatin (UMIN000034222). The aim of this study was to investigate the clinical significance of ERBB2 amplification (amp.) and TMB-H for this new combination therapy.
Methods
Patients were treated with S-1 80 mg/m2/day or Capecitabine 2000 mg/m2/day on days 1-14 with oxaliplatin 130 mg/m2, N-mab 360mg, and T-mab 8mg/kg for initial treatment, and subsequently with 6 mg/kg on day, repeated every 3 weeks. Pretreatment primary tumor samples were collected for whole exome sequencing (WES) and immunohistochemistry (IHC).
Results
Among 42 patients enrolled in this clinical trial, WES was performed on 23 patients. ERBB2 amp. (≥ 6 copies) was observed in 15 patients (65%). Fourteen (93.3%) of these 15 patients with ERBB2 amp. and 2 (25%) of 8 patients without ERBB2 amp. were IHC3+, respectively (p = 0.002). There was a weak positive correlation between ERBB2 copy number and PFS (r = 0.449, p = 0.032). Patients with ERBB2 amp. showed longer PFS than those without ERBB2 amp. (mPFS: 16.3 vs 5.8 months, HR = 0.70 [95%CI 0.24-2.09], p = 0.522). In particular, 7 patients with high ERBB2 copy number (≥ 50) showed remarkably longer PFS and a higher response rate than 16 patients with < 50 (mPFS: 20.8 vs 6.7 months, HR = 0.40 [95%CI 0.12-1.30], p = 0.117, response rate: 100% vs 63%, p = 0.124). TMB-H (≥ 10 muts/Mb) was observed in 6 patients (26%), and these patients also showed substantially longer PFS than those with TMB-L (mPFS: 16.3 vs 9.2 months, HR = 0.43 [95%CI 0.12-1.51], p = 0.172) with a comparable response rate (83% vs 73%). Eleven patients with ERBB2 copy number ≥ 50 or TMB-H showed significantly longer PFS (mPFS: 20.8 vs 5.8 months, HR = 0.28 [95%CI 0.09-0.88], p = 0.021) and OS (mOS: not reached vs 15.0 months, HR = 0.10 [95%CI 0.01-0.78], p = 0.007) and a higher response rate (91% vs 58%, p = 0.155) than the remaining 12 patients.
Conclusions
High ERBB2 copy number and TMB-H may be a candidate biomarker for this new combination therapy including T-mab and N-mab in patients with HER2-positive advanced gastric cancer.
Clinical trial identification
UMIN000034222.
Editorial acknowledgement
Legal entity responsible for the study
Daisuke Takahari.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
H. Shoji: Financial Interests, Personal, Advisory Board: Ono Pharmaceutical Co., Ltd., Zymeworks inc.; Financial Interests, Institutional, Local PI: Ono Pharmaceutical Co., Ltd., MSD, Astellas, Amgen, Daiichi Sankyo; Financial Interests, Institutional, Funding: Ono Pharmaceutical Co., Ltd., Takeda Pharmaceuticals. K. Minashi: Financial Interests, Institutional, Research Grant: Amgen, Taiho Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Astellas Pharmaceutical Co., Ltd. H. Hara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, MSD, Ono, Bayer, Chugai, Lilly, Merck Biopharma, Taiho, Takeda, Yakult, Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono, Taiho, ALX oncology. N. Boku: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Eli Lilly, Ono Pharmaceutical, Taiho, Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Takeda Pharmaceutical, Ono Pharmaceutical. K. Yamaguchi: Financial Interests, Personal, Invited Speaker: Taiho; Financial Interests, Personal, Expert Testimony: Daiichi Sankyo, Bristol Myers Squibb, Ono, Eli Lilly Japan; Financial Interests, Institutional, Funding: Taiho. All other authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21